APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Osteoarthritis Pain Drugs

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

Selected research

Market Outlook & Growth Opportunities

Global Osteoarthritis Pain Drugs Market Outlook and Growth Opportunities 2026

Report ID 17402085042 January 2026213 pages

Choose your research edition.

Industry ResearchOsteoarthritis Pain Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Osteoarthritis Pain Drugs Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Osteoarthritis Pain Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osteoarthritis Pain Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Osteoarthritis Pain Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers.

The major players in global Methylcyclohexane market include Pfizer, Johnson & Johnson, GlaxoSmithKline, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Oral is the main type, with a share over 50%. Personal Care is the main application, which holds a share about 90%.

This report provides an overview of the global Osteoarthritis Pain Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Osteoarthritis Pain Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Osteoarthritis Pain Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Osteoarthritis Pain Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Osteoarthritis Pain Drugs Segment by Company

Pfizer

Bayer

SK Chemicals

GSK

Sanofi

Crystal Genomics

Johnson & Johnson

Sino Biopharmaceutical

Haohai Biological

Zhejiang Chengyi Pharmaceutical

Freda

Bright Future

Jingfeng Pharmaceutical

Chugai Pharmaceutical

Mikasa Seiyaku

Taisho Pharmaceutical

Seikagaku Corporation

GlaxoSmithKline

Eli Lilly

Novartis

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Osteoarthritis Pain Drugs Segment by Type

Oral

Injection

External

Osteoarthritis Pain Drugs Segment by Application

Medical Care

Personal Care

Osteoarthritis Pain Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Osteoarthritis Pain Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Osteoarthritis Pain Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Osteoarthritis Pain Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Osteoarthritis Pain Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoarthritis Pain Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osteoarthritis Pain Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoarthritis Pain Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Osteoarthritis Pain Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Osteoarthritis Pain Drugs industry.

Chapter 3: Detailed analysis of Osteoarthritis Pain Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Osteoarthritis Pain Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Osteoarthritis Pain Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Osteoarthritis Pain Drugs Industry Trends Table 2. Osteoarthritis Pain Drugs Industry Drivers Table 3. Osteoarthritis Pain Drugs Industry Opportunities and Challenges Table 4. Osteoarthritis Pain Drugs Industry Restraints Table 5. Global Osteoarthritis Pain Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Osteoarthritis Pain Drugs Revenue Share by Company (2021-2026) Table 7. Global Osteoarthritis Pain Drugs Sales Volume by Company (M Dose) & (2021-2026) Table 8. Global Osteoarthritis Pain Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Osteoarthritis Pain Drugs Average Price (US$/Dose) of Company (2021-2026) Table 10. Global Osteoarthritis Pain Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Osteoarthritis Pain Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Osteoarthritis Pain Drugs Company, Product Type & Application Table 13. Global Osteoarthritis Pain Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Osteoarthritis Pain Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injection Table 19. Significant Companies of External Table 20. Global Osteoarthritis Pain Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (M Dose) Table 21. Global Osteoarthritis Pain Drugs Sales Volume by Type (2021-2026) & (M Dose) Table 22. Global Osteoarthritis Pain Drugs Sales Volume by Type (2027-2032) & (M Dose) Table 23. Global Osteoarthritis Pain Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Osteoarthritis Pain Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Osteoarthritis Pain Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Osteoarthritis Pain Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Osteoarthritis Pain Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Osteoarthritis Pain Drugs Sales Value Share by Type (2021-2026) Table 29. Global Osteoarthritis Pain Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Medical Care Table 31. Significant Companies of Personal Care Table 32. Global Osteoarthritis Pain Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (M Dose) Table 33. Global Osteoarthritis Pain Drugs Sales Volume by Application (2021-2026) & (M Dose) Table 34. Global Osteoarthritis Pain Drugs Sales Volume by Application (2027-2032) & (M Dose) Table 35. Global Osteoarthritis Pain Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Osteoarthritis Pain Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Osteoarthritis Pain Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Osteoarthritis Pain Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Osteoarthritis Pain Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Osteoarthritis Pain Drugs Sales Value Share by Application (2021-2026) Table 41. Global Osteoarthritis Pain Drugs Sales Value Share by Application (2027-2032) Table 42. Global Osteoarthritis Pain Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Dose) Table 43. Global Osteoarthritis Pain Drugs Sales by Region (2021-2026) & (M Dose) Table 44. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2021-2026) Table 45. Global Osteoarthritis Pain Drugs Sales by Region (2027-2032) & (M Dose) Table 46. Global Osteoarthritis Pain Drugs Sales Market Share by Region (2027-2032) Table 47. Global Osteoarthritis Pain Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Osteoarthritis Pain Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Osteoarthritis Pain Drugs Sales Value Share by Region (2021-2026) Table 50. Global Osteoarthritis Pain Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Osteoarthritis Pain Drugs Sales Value Share by Region (2027-2032) Table 52. Global Osteoarthritis Pain Drugs Market Average Price (US$/Dose) by Region (2021-2026) Table 53. Global Osteoarthritis Pain Drugs Market Average Price (US$/Dose) by Region (2027-2032) Table 54. Global Osteoarthritis Pain Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Dose) Table 55. Global Osteoarthritis Pain Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Osteoarthritis Pain Drugs Sales by Country (2021-2026) & (M Dose) Table 57. Global Osteoarthritis Pain Drugs Sales Market Share by Country (2021-2026) Table 58. Global Osteoarthritis Pain Drugs Sales by Country (2027-2032) & (M Dose) Table 59. Global Osteoarthritis Pain Drugs Sales Market Share by Country (2027-2032) Table 60. Global Osteoarthritis Pain Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Osteoarthritis Pain Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Osteoarthritis Pain Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Osteoarthritis Pain Drugs Sales Value Market Share by Country (2027-2032) Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 67. Pfizer Osteoarthritis Pain Drugs Product Portfolio Table 68. Pfizer Recent Development Table 69. Bayer Company Information Table 70. Bayer Business Overview Table 71. Bayer Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 72. Bayer Osteoarthritis Pain Drugs Product Portfolio Table 73. Bayer Recent Development Table 74. SK Chemicals Company Information Table 75. SK Chemicals Business Overview Table 76. SK Chemicals Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 77. SK Chemicals Osteoarthritis Pain Drugs Product Portfolio Table 78. SK Chemicals Recent Development Table 79. GSK Company Information Table 80. GSK Business Overview Table 81. GSK Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 82. GSK Osteoarthritis Pain Drugs Product Portfolio Table 83. GSK Recent Development Table 84. Sanofi Company Information Table 85. Sanofi Business Overview Table 86. Sanofi Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 87. Sanofi Osteoarthritis Pain Drugs Product Portfolio Table 88. Sanofi Recent Development Table 89. Crystal Genomics Company Information Table 90. Crystal Genomics Business Overview Table 91. Crystal Genomics Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 92. Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio Table 93. Crystal Genomics Recent Development Table 94. Johnson & Johnson Company Information Table 95. Johnson & Johnson Business Overview Table 96. Johnson & Johnson Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 97. Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio Table 98. Johnson & Johnson Recent Development Table 99. Sino Biopharmaceutical Company Information Table 100. Sino Biopharmaceutical Business Overview Table 101. Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 102. Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 103. Sino Biopharmaceutical Recent Development Table 104. Haohai Biological Company Information Table 105. Haohai Biological Business Overview Table 106. Haohai Biological Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 107. Haohai Biological Osteoarthritis Pain Drugs Product Portfolio Table 108. Haohai Biological Recent Development Table 109. Zhejiang Chengyi Pharmaceutical Company Information Table 110. Zhejiang Chengyi Pharmaceutical Business Overview Table 111. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 112. Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 113. Zhejiang Chengyi Pharmaceutical Recent Development Table 114. Freda Company Information Table 115. Freda Business Overview Table 116. Freda Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 117. Freda Osteoarthritis Pain Drugs Product Portfolio Table 118. Freda Recent Development Table 119. Bright Future Company Information Table 120. Bright Future Business Overview Table 121. Bright Future Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 122. Bright Future Osteoarthritis Pain Drugs Product Portfolio Table 123. Bright Future Recent Development Table 124. Jingfeng Pharmaceutical Company Information Table 125. Jingfeng Pharmaceutical Business Overview Table 126. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 127. Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 128. Jingfeng Pharmaceutical Recent Development Table 129. Chugai Pharmaceutical Company Information Table 130. Chugai Pharmaceutical Business Overview Table 131. Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 132. Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 133. Chugai Pharmaceutical Recent Development Table 134. Mikasa Seiyaku Company Information Table 135. Mikasa Seiyaku Business Overview Table 136. Mikasa Seiyaku Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 137. Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio Table 138. Mikasa Seiyaku Recent Development Table 139. Taisho Pharmaceutical Company Information Table 140. Taisho Pharmaceutical Business Overview Table 141. Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 142. Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 143. Taisho Pharmaceutical Recent Development Table 144. Seikagaku Corporation Company Information Table 145. Seikagaku Corporation Business Overview Table 146. Seikagaku Corporation Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 147. Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio Table 148. Seikagaku Corporation Recent Development Table 149. GlaxoSmithKline Company Information Table 150. GlaxoSmithKline Business Overview Table 151. GlaxoSmithKline Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 152. GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio Table 153. GlaxoSmithKline Recent Development Table 154. Eli Lilly Company Information Table 155. Eli Lilly Business Overview Table 156. Eli Lilly Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 157. Eli Lilly Osteoarthritis Pain Drugs Product Portfolio Table 158. Eli Lilly Recent Development Table 159. Novartis Company Information Table 160. Novartis Business Overview Table 161. Novartis Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 162. Novartis Osteoarthritis Pain Drugs Product Portfolio Table 163. Novartis Recent Development Table 164. Horizon Pharma Company Information Table 165. Horizon Pharma Business Overview Table 166. Horizon Pharma Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 167. Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio Table 168. Horizon Pharma Recent Development Table 169. Abbott Company Information Table 170. Abbott Business Overview Table 171. Abbott Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 172. Abbott Osteoarthritis Pain Drugs Product Portfolio Table 173. Abbott Recent Development Table 174. Mylan Company Information Table 175. Mylan Business Overview Table 176. Mylan Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 177. Mylan Osteoarthritis Pain Drugs Product Portfolio Table 178. Mylan Recent Development Table 179. Daiichi Sankyo Company Information Table 180. Daiichi Sankyo Business Overview Table 181. Daiichi Sankyo Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 182. Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio Table 183. Daiichi Sankyo Recent Development Table 184. TEVA Company Information Table 185. TEVA Business Overview Table 186. TEVA Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 187. TEVA Osteoarthritis Pain Drugs Product Portfolio Table 188. TEVA Recent Development Table 189. Almatica Pharma Company Information Table 190. Almatica Pharma Business Overview Table 191. Almatica Pharma Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 192. Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio Table 193. Almatica Pharma Recent Development Table 194. Astellas Pharma Company Information Table 195. Astellas Pharma Business Overview Table 196. Astellas Pharma Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 197. Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio Table 198. Astellas Pharma Recent Development Table 199. Tide Pharmaceutical Company Information Table 200. Tide Pharmaceutical Business Overview Table 201. Tide Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 202. Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 203. Tide Pharmaceutical Recent Development Table 204. Iroko Pharmaceuticals Company Information Table 205. Iroko Pharmaceuticals Business Overview Table 206. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 207. Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio Table 208. Iroko Pharmaceuticals Recent Development Table 209. Hengrui Pharmaceutical Company Information Table 210. Hengrui Pharmaceutical Business Overview Table 211. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 212. Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio Table 213. Hengrui Pharmaceutical Recent Development Table 214. Key Raw Materials Table 215. Raw Materials Key Suppliers Table 216. Osteoarthritis Pain Drugs Distributors List Table 217. Osteoarthritis Pain Drugs Customers List Table 218. Research Programs/Design for This Report Table 219. Authors List of This Report Table 220. Secondary Sources Table 221. Primary Sources List of Figures Figure 1. Osteoarthritis Pain Drugs Product Image Figure 2. Global Osteoarthritis Pain Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Osteoarthritis Pain Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Osteoarthritis Pain Drugs Sales (2021-2032) & (M Dose) Figure 5. Global Osteoarthritis Pain Drugs Sales Average Price (US$/Dose) & (2021-2032) Figure 6. Global Osteoarthritis Pain Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injection Image Figure 11. External Image Figure 12. Global Osteoarthritis Pain Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (M Dose) Figure 13. Global Osteoarthritis Pain Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Osteoarthritis Pain Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Osteoarthritis Pain Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Osteoarthritis Pain Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Osteoarthritis Pain Drugs Sales Value Share by Type (2021-2032) Figure 18. Medical Care Image Figure 19. Personal Care Image Figure 20. Global Osteoarthritis Pain Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (M Dose) Figure 21. Global Osteoarthritis Pain Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Osteoarthritis Pain Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Osteoarthritis Pain Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Osteoarthritis Pain Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Osteoarthritis Pain Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Osteoarthritis Pain Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Dose) Figure 27. Global Osteoarthritis Pain Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Osteoarthritis Pain Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Osteoarthritis Pain Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Osteoarthritis Pain Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Osteoarthritis Pain Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Osteoarthritis Pain Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Osteoarthritis Pain Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Osteoarthritis Pain Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Osteoarthritis Pain Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Osteoarthritis Pain Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Osteoarthritis Pain Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Osteoarthritis Pain Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Osteoarthritis Pain Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Osteoarthritis Pain Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Osteoarthritis Pain Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
  • External
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Pfizer
  • Bayer
  • SK Chemicals
  • GSK
  • Sanofi
  • Crystal Genomics
  • Johnson & Johnson
  • Sino Biopharmaceutical
  • Haohai Biological
  • Zhejiang Chengyi Pharmaceutical
  • Freda
  • Bright Future
  • Jingfeng Pharmaceutical
  • Chugai Pharmaceutical
  • Mikasa Seiyaku
  • Taisho Pharmaceutical
  • Seikagaku Corporation
  • GlaxoSmithKline
  • Eli Lilly
  • Novartis
  • Horizon Pharma
  • Abbott
  • Mylan
  • Daiichi Sankyo
  • TEVA
  • Almatica Pharma
  • Astellas Pharma
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Hengrui Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Osteoarthritis Pain Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Osteoarthritis Pain Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Osteoarthritis Pain Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Osteoarthritis Pain Drugs Market Dynamics
  1. 2.1 Osteoarthritis Pain Drugs Industry Trends
  2. 2.2 Osteoarthritis Pain Drugs Industry Drivers
  3. 2.3 Osteoarthritis Pain Drugs Industry Opportunities and Challenges
  4. 2.4 Osteoarthritis Pain Drugs Industry Restraints
3 Osteoarthritis Pain Drugs Market by Company
  1. 3.1 Global Osteoarthritis Pain Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Osteoarthritis Pain Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Osteoarthritis Pain Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Osteoarthritis Pain Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Osteoarthritis Pain Drugs Company Ranking (2024-2026)
  6. 3.6 Global Osteoarthritis Pain Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Osteoarthritis Pain Drugs Company Product Type and Application
  8. 3.8 Global Osteoarthritis Pain Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Osteoarthritis Pain Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Osteoarthritis Pain Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Osteoarthritis Pain Drugs Market by Type
  1. 4.1 Osteoarthritis Pain Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.1.3 External
  5. 4.2 Global Osteoarthritis Pain Drugs Sales Volume by Type
  6. 4.2.1 Global Osteoarthritis Pain Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Osteoarthritis Pain Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Osteoarthritis Pain Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Osteoarthritis Pain Drugs Sales Value by Type
  10. 4.3.1 Global Osteoarthritis Pain Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Osteoarthritis Pain Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Osteoarthritis Pain Drugs Sales Value Share by Type (2021-2032)
5 Osteoarthritis Pain Drugs Market by Application
  1. 5.1 Osteoarthritis Pain Drugs Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Osteoarthritis Pain Drugs Sales Volume by Application
  5. 5.2.1 Global Osteoarthritis Pain Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Osteoarthritis Pain Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Osteoarthritis Pain Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Osteoarthritis Pain Drugs Sales Value by Application
  9. 5.3.1 Global Osteoarthritis Pain Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Osteoarthritis Pain Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Osteoarthritis Pain Drugs Sales Value Share by Application (2021-2032)
6 Osteoarthritis Pain Drugs Regional Sales and Value Analysis
  1. 6.1 Global Osteoarthritis Pain Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Osteoarthritis Pain Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Osteoarthritis Pain Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Osteoarthritis Pain Drugs Sales by Region (2027-2032)
  5. 6.3 Global Osteoarthritis Pain Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Osteoarthritis Pain Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Osteoarthritis Pain Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Osteoarthritis Pain Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Osteoarthritis Pain Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Osteoarthritis Pain Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Osteoarthritis Pain Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Osteoarthritis Pain Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Osteoarthritis Pain Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Osteoarthritis Pain Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Osteoarthritis Pain Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Osteoarthritis Pain Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Osteoarthritis Pain Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Osteoarthritis Pain Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Osteoarthritis Pain Drugs Sales Value Share by Country, 2025 VS 2032
7 Osteoarthritis Pain Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Osteoarthritis Pain Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Osteoarthritis Pain Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Osteoarthritis Pain Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Osteoarthritis Pain Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Osteoarthritis Pain Drugs Sales by Country (2027-2032)
  6. 7.4 Global Osteoarthritis Pain Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Osteoarthritis Pain Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Osteoarthritis Pain Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Osteoarthritis Pain Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Osteoarthritis Pain Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Osteoarthritis Pain Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Osteoarthritis Pain Drugs Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Osteoarthritis Pain Drugs Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 SK Chemicals
  14. 8.3.1 SK Chemicals Company Information
  15. 8.3.2 SK Chemicals Business Overview
  16. 8.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 SK Chemicals Osteoarthritis Pain Drugs Product Portfolio
  18. 8.3.5 SK Chemicals Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Osteoarthritis Pain Drugs Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Osteoarthritis Pain Drugs Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Crystal Genomics
  32. 8.6.1 Crystal Genomics Company Information
  33. 8.6.2 Crystal Genomics Business Overview
  34. 8.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio
  36. 8.6.5 Crystal Genomics Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
  43. 8.8 Sino Biopharmaceutical
  44. 8.8.1 Sino Biopharmaceutical Company Information
  45. 8.8.2 Sino Biopharmaceutical Business Overview
  46. 8.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  48. 8.8.5 Sino Biopharmaceutical Recent Developments
  49. 8.9 Haohai Biological
  50. 8.9.1 Haohai Biological Company Information
  51. 8.9.2 Haohai Biological Business Overview
  52. 8.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Haohai Biological Osteoarthritis Pain Drugs Product Portfolio
  54. 8.9.5 Haohai Biological Recent Developments
  55. 8.10 Zhejiang Chengyi Pharmaceutical
  56. 8.10.1 Zhejiang Chengyi Pharmaceutical Company Information
  57. 8.10.2 Zhejiang Chengyi Pharmaceutical Business Overview
  58. 8.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  60. 8.10.5 Zhejiang Chengyi Pharmaceutical Recent Developments
  61. 8.11 Freda
  62. 8.11.1 Freda Company Information
  63. 8.11.2 Freda Business Overview
  64. 8.11.3 Freda Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Freda Osteoarthritis Pain Drugs Product Portfolio
  66. 8.11.5 Freda Recent Developments
  67. 8.12 Bright Future
  68. 8.12.1 Bright Future Company Information
  69. 8.12.2 Bright Future Business Overview
  70. 8.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bright Future Osteoarthritis Pain Drugs Product Portfolio
  72. 8.12.5 Bright Future Recent Developments
  73. 8.13 Jingfeng Pharmaceutical
  74. 8.13.1 Jingfeng Pharmaceutical Company Information
  75. 8.13.2 Jingfeng Pharmaceutical Business Overview
  76. 8.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  78. 8.13.5 Jingfeng Pharmaceutical Recent Developments
  79. 8.14 Chugai Pharmaceutical
  80. 8.14.1 Chugai Pharmaceutical Company Information
  81. 8.14.2 Chugai Pharmaceutical Business Overview
  82. 8.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  84. 8.14.5 Chugai Pharmaceutical Recent Developments
  85. 8.15 Mikasa Seiyaku
  86. 8.15.1 Mikasa Seiyaku Company Information
  87. 8.15.2 Mikasa Seiyaku Business Overview
  88. 8.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio
  90. 8.15.5 Mikasa Seiyaku Recent Developments
  91. 8.16 Taisho Pharmaceutical
  92. 8.16.1 Taisho Pharmaceutical Company Information
  93. 8.16.2 Taisho Pharmaceutical Business Overview
  94. 8.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  96. 8.16.5 Taisho Pharmaceutical Recent Developments
  97. 8.17 Seikagaku Corporation
  98. 8.17.1 Seikagaku Corporation Company Information
  99. 8.17.2 Seikagaku Corporation Business Overview
  100. 8.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio
  102. 8.17.5 Seikagaku Corporation Recent Developments
  103. 8.18 GlaxoSmithKline
  104. 8.18.1 GlaxoSmithKline Company Information
  105. 8.18.2 GlaxoSmithKline Business Overview
  106. 8.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio
  108. 8.18.5 GlaxoSmithKline Recent Developments
  109. 8.19 Eli Lilly
  110. 8.19.1 Eli Lilly Company Information
  111. 8.19.2 Eli Lilly Business Overview
  112. 8.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Eli Lilly Osteoarthritis Pain Drugs Product Portfolio
  114. 8.19.5 Eli Lilly Recent Developments
  115. 8.20 Novartis
  116. 8.20.1 Novartis Company Information
  117. 8.20.2 Novartis Business Overview
  118. 8.20.3 Novartis Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Novartis Osteoarthritis Pain Drugs Product Portfolio
  120. 8.20.5 Novartis Recent Developments
  121. 8.21 Horizon Pharma
  122. 8.21.1 Horizon Pharma Company Information
  123. 8.21.2 Horizon Pharma Business Overview
  124. 8.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio
  126. 8.21.5 Horizon Pharma Recent Developments
  127. 8.22 Abbott
  128. 8.22.1 Abbott Company Information
  129. 8.22.2 Abbott Business Overview
  130. 8.22.3 Abbott Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Abbott Osteoarthritis Pain Drugs Product Portfolio
  132. 8.22.5 Abbott Recent Developments
  133. 8.23 Mylan
  134. 8.23.1 Mylan Company Information
  135. 8.23.2 Mylan Business Overview
  136. 8.23.3 Mylan Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Mylan Osteoarthritis Pain Drugs Product Portfolio
  138. 8.23.5 Mylan Recent Developments
  139. 8.24 Daiichi Sankyo
  140. 8.24.1 Daiichi Sankyo Company Information
  141. 8.24.2 Daiichi Sankyo Business Overview
  142. 8.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio
  144. 8.24.5 Daiichi Sankyo Recent Developments
  145. 8.25 TEVA
  146. 8.25.1 TEVA Company Information
  147. 8.25.2 TEVA Business Overview
  148. 8.25.3 TEVA Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 TEVA Osteoarthritis Pain Drugs Product Portfolio
  150. 8.25.5 TEVA Recent Developments
  151. 8.26 Almatica Pharma
  152. 8.26.1 Almatica Pharma Company Information
  153. 8.26.2 Almatica Pharma Business Overview
  154. 8.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio
  156. 8.26.5 Almatica Pharma Recent Developments
  157. 8.27 Astellas Pharma
  158. 8.27.1 Astellas Pharma Company Information
  159. 8.27.2 Astellas Pharma Business Overview
  160. 8.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio
  162. 8.27.5 Astellas Pharma Recent Developments
  163. 8.28 Tide Pharmaceutical
  164. 8.28.1 Tide Pharmaceutical Company Information
  165. 8.28.2 Tide Pharmaceutical Business Overview
  166. 8.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  167. 8.28.4 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  168. 8.28.5 Tide Pharmaceutical Recent Developments
  169. 8.29 Iroko Pharmaceuticals
  170. 8.29.1 Iroko Pharmaceuticals Company Information
  171. 8.29.2 Iroko Pharmaceuticals Business Overview
  172. 8.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  173. 8.29.4 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio
  174. 8.29.5 Iroko Pharmaceuticals Recent Developments
  175. 8.30 Hengrui Pharmaceutical
  176. 8.30.1 Hengrui Pharmaceutical Company Information
  177. 8.30.2 Hengrui Pharmaceutical Business Overview
  178. 8.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Value and Gross Margin (2021-2026)
  179. 8.30.4 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
  180. 8.30.5 Hengrui Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Osteoarthritis Pain Drugs Value Chain Analysis
  2. 9.1.1 Osteoarthritis Pain Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Osteoarthritis Pain Drugs Sales Mode & Process
  6. 9.2 Osteoarthritis Pain Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Osteoarthritis Pain Drugs Distributors
  9. 9.2.3 Osteoarthritis Pain Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst